Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma

被引：0
|
作者：
Bai, Xue
Li, Mei
Chen, Yu
Si, Lu
Chen, Jing
Pu, Xingxiang
Cheng, Ying
Zou, Zhengyun
Zhao, Shiwei
Li, Tao
Cai, Shengli
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Renal Canc & Melanoma, Beijing, Peoples R China
[2] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[3] Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Clin Oncol Sch, Fuzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China
[5] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Med Sch, Changsha, Peoples R China
[6] Jilin Canc Hosp, Dept Med Thorac Oncol, Changchun, Peoples R China
[7] Nanjing Univ, Drum Tower Hosp, Med Sch, Comprehens Canc Ctr, Nanjing, Peoples R China
[8] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China
[9] Nanjing Leads Biolabs Co Ltd, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9541
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study
    Yang, Yunpeng
    Zhao, Yuanyuan
    Fang, Wenfeng
    Huang, Yan
    Zhang, Yaxiong
    Ba, Yi
    Wang, Zhen
    Deng, Chao
    Hu, Desheng
    Wang, Wei
    Li, Guiling
    Luo, Suxia
    Fu, Zhichao
    Zhu, Haisheng
    Wang, Huili
    Zhao, Shiwei
    Li, Tao
    Cai, Charles
    Zhang, Li
    CANCER RESEARCH, 2024, 84 (07)
  • [2] Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase., open-label, multicenter, dose escalation/expansion study.
    Bai, Xue
    Li, Mei
    Pu, Xingxiang
    Cheng, Ying
    Chen, Jing
    Jiang, Yu
    Chen, Xue
    Liu, Jingjing
    Fan, Li
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
    Chen, Gang
    Sun, Dong-Chen
    Ba, Yi
    Zhang, Ya-Xiong
    Zhou, Ting
    Zhao, Yuan-Yuan
    Zhao, Hong-Yun
    Fang, Wen-Feng
    Huang, Yan
    Wang, Zhen
    Deng, Chao
    Hu, De-Sheng
    Wang, Wei
    Lin, Jin-Guan
    Li, Gui-Ling
    Luo, Su-Xia
    Fu, Zhi-Chao
    Zhu, Hai-Sheng
    Wang, Hui-Li
    Cai, Sheng-Li
    Kang, Xiao-Qiang
    Zhang, Li
    Yang, Yun-Peng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [4] Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study
    Yang, Yunpeng
    Chen, Yu
    Qu, Song
    Liu, Lei
    Chen, Lisha
    Yang, Kunyu
    Huang, Xiaoming
    Li, Jingao
    Wang, Rensheng
    Zhu, Haisheng
    Zhao, Shiwei
    Li, Tao
    Cai, Shengli
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Phase I study of LBL-007, a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody in patients with advanced solid tumors.
    Shi, Yuankai
    Luo, Suxia
    Zhou, Huan
    Zhou, Shengyu
    An, Shan
    Wang, Zishu
    Yang, Sheng
    Li, Ning
    Li, Xiaoli
    Yang, Xinyi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and < for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and < for clinical potential in solid tumors such as HNSCC
    Zhu, Hengrui
    Zhang, Jinhui
    Yan, Han
    Ding, Xiao
    Yang, Juan
    Jiang, Yu
    Deng, Minjuan
    Song, Haoxuan
    Ping, Fangfang
    Sun, Fuyun
    Li, Xiaoyu
    Zhang, Lijie
    Jiang, Bin
    Song, Weiwei
    Shen, Zhirong
    Jin, Wei
    Zhang, Jiyuan
    Zhang, Yun
    CANCER RESEARCH, 2024, 84 (06)
  • [7] BGB-A317-LBL-007-202: A phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC)
    Park, Sook Ryun
    Chen, Ming-Huang
    Dechaphunkul, Arunee
    Ding, Ningning
    Lin, Xiao
    Zhang, Jinghui
    Li, Vivian
    Li, Qiao
    Ba, Yi
    CANCER RESEARCH, 2024, 84 (07)
  • [8] Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM.
    Lim, Michael
    Ye, Xiaobu
    Piotrowski, Anna F.
    Desai, Arati Suvas
    Ahluwalia, Manmeet Singh
    Walbert, Tobias
    Fisher, Joy D.
    Desideri, Serena
    Nabors, Louis B.
    Wen, Patrick Y.
    Grossman, Stuart A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] A Phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC
    Kim, Miso
    ONCOLOGIST, 2024, 29 : S7 - S7
  • [10] A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC
    Cho, Byoung Chul
    Hamid, Omid
    Zhu, Xinhua
    Keam, Bhumsuk
    Kaczmar, John M.
    Williamson, Stephen K.
    Birnbaum, Ariel E.
    Dowlati, Afshin
    Dy, Grace K.
    Hager, Steven Jeffrey
    Lynce, Filipa
    McDermott, Raymond S.
    Sarker, Debashis
    Weise, Amy M.
    Yap, Timothy A.
    Yilmaz, Emrullah
    Fang, Fang
    Mani, Jayakumar
    Kroog, Glenn Scott
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345